甲状腺乳头状癌的促甲状腺激素抑制治疗:一项医生调查研究
该研究调查了2018-2019年乔治亚州和洛杉矶SEER登记处的内分泌科医生和外科医生对甲状腺乳头状癌患者促甲状腺激素(TSH)抑制治疗的态度。结果显示,80.4%的医生对中危患者、48.8%对低危患者、29.7%对极低危患者可能推荐TSH抑制(TSH<0.5 mIU/L)。外科医生较内分泌科医生在中危患者中更少推荐抑制,高患者量医生在低危和极低危患者中更少抑制。
要点
- 多数医生对中危甲状腺乳头状癌患者推荐TSH抑制,低危和极低危患者中也有相当比例被推荐抑制。
- 外科医生相比内分泌科医生在中危患者中更少推荐TSH抑制。
- 高甲状腺癌患者量的医生在低危和极低危患者中更少推荐TSH抑制。
核心结论
- 许多低危甲状腺癌患者仍接受抑制性剂量的甲状腺激素治疗,需要更高质量研究指导管理和理解指南采纳障碍。
研究设计与样本
- 对乔治亚州和洛杉矶SEER登记处甲状腺癌患者所确定的内分泌科医生和外科医生进行2018-2019年调查,应答率69%(448/654)。
主要发现
- 80.4%的医生对中危甲状腺乳头状癌患者可能/极可能推荐TSH抑制(TSH<0.5 mIU/L)。
- 48.8%的医生对低危患者可能/极可能推荐TSH抑制,29.7%对极低危患者可能/极可能推荐。
- 外科医生较内分泌科医生在中危患者中更少推荐TSH抑制(OR=0.36,95%CI 0.19-0.69)。
- 年患者量>40例的医生较0-20例者更少在低危(OR=0.53,95%CI 0.30-0.96)和极低危(OR=0.49,95%CI 0.24-0.99)患者中抑制TSH。
- 估计复发可能性更高的医生更可能在极低危患者中抑制TSH(OR=2.34,95%CI 1.91-4.59)。
关键数值与推荐
- 当前指南推荐不在低危分化型甲状腺癌患者中使用TSH抑制。
- TSH抑制定义为TSH<0.5 mIU/L。
临床怎么用
- 临床医生应遵循指南,避免对低危和极低危甲状腺乳头状癌患者常规使用TSH抑制。
- 内分泌科医生和外科医生应加强沟通,统一对中危患者TSH抑制的推荐。
局限性
- 研究为调查设计,可能受应答偏倚影响。
- 仅纳入乔治亚州和洛杉矶SEER登记处的医生,结果可能不能推广至其他地区。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Current guidelines recommend against thyrotropin (TSH) suppression in low-risk differentiated thyroid cancer patients; however, physician practices remain underexplored. Our objective was to understand treating physicians' approach to TSH suppression in patients with papillary thyroid cancer. Methods: Endocrinologists and surgeons identified by thyroid cancer patients from the Surveillance, Epidemiology, and End Results registries of Georgia and Los Angeles were surveyed in 2018-2019. Physicians were asked to report how likely they were to recommend TSH suppression (i.e., TSH <0.5 mIU/L) in three clinical scenarios: patients with intermediate-risk, low-risk, and very low-risk papillary thyroid cancer. Responses were measured on a 4-point Likert scale (extremely unlikely to extremely likely). Multivariable logistic regressions were performed to determine physician characteristics associated with recommending TSH suppression in each of the aforementioned scenarios. Results: Response rate was 69% (448/654). Overall, 80.4% of physicians were likely/extremely likely to recommend TSH suppression for a patient with an intermediate-risk papillary thyroid cancer, 48.8% for a patient with low-risk papillary thyroid cancer, and 29.7% for a patient with very low-risk papillary thyroid cancer. Surgeons were less likely to recommend TSH suppression for an intermediate-risk papillary thyroid cancer patient (odds ratio [OR] = 0.36 [95% confidence interval, CI, 0.19-0.69]) compared with endocrinologists. Physicians with higher thyroid cancer patient volume were less likely to suppress TSH in low-risk and very low-risk papillary thyroid cancer patients (i.e., >40 patients per year, OR = 0.53 [CI 0.30-0.96]; OR = 0.49 [CI 0.24-0.99], respectively, compared with 0-20 patients per year). Physicians who estimated higher likelihood of recurrence were more likely to suppress TSH in a patient with very low-risk papillary thyroid cancer (OR = 2.34 [CI 1.91-4.59]). Conclusions: Many patients with low-risk thyroid cancer continue to be treated with suppressive doses of thyroid hormone, emphasizing the need for more high-quality research to guide thyroid cancer management, as well as better understanding of barriers that hinder guideline adoption.
引用
- Papaleontiou M, Chen DW, Banerjee M, et al. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study. Thyroid. 2021. PMID: 33779292. doi:10.1089/thy.2021.0033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。